IMPROVEMENT OF OVERALL SURVIVAL IN DANISH MULTIPLE MYELOMA PATIENTS AFTER 2008; A POPULATION-BASED STUDY FROM THE DANISH NATIONAL MULTIPLE MYELOMA REGISTRY
(Abstract release date: 05/19/16)
EHA Library. Abildgaard N. 06/09/16; 132846; E1297
Prof. Dr. Niels Abildgaard
Contributions
Contributions
Abstract
Abstract: E1297
Type: Eposter Presentation
Background
Improvement of overall survival in multiple myeloma (MM) after 2000 has been reported and it has been associated with introduction of new therapeutics (Kumar, Blood 2008,111,2516-20 & Kumar, Leukemia 2014,28,1122-28). The Danish National Multiple Myeloma Registry (DMMR) was established in 2005 and has registered all patients with newly diagnosed multiple myeloma in Denmark since 1 January 2005. The Danish Myeloma Study Group (DMSG) published in 2009 the first National evidence-based guideline for treatment of MM in Denmark. The guideline recommended bortezomib based induction treatment for younger MM patients prior to HDT and for elderly patients with aggressive disease presentation and adverse cytogenetics. Moreover, lenalidomide was included in the algorithm for treatment of relapsed/progressive disease.
Aims
We aimed to analyse population-based overall survival in Danish MM patients in relation to shift in National treatment guidelines in 2009.
Methods
At 30 June 2015, the database had registered a total of 2907 patients, 991 patients <65 years and 1916 patients >65 years, with newly diagnosed treatment-demanding MM. Age-adjusted survival analyses were done per 1 September 2015.
Results
Comparing OS for patients diagnosed in the two time periods 2005-2008 and 2009-2015, we found a highly significant improved age-corrected OS in patients >65 years, increasing from median 24.7 months (2005-08) to median 32.9 months (2009-15) (p=0.003). For patients <65 years at diagnosis the overall survival also improved from median 67 months (2005-2008) to above 74 months (median OS not yet reached) (2009-2015) (p=0.02). In patients >80 years at diagnosis the survival is poor and has not improved significantly between the 2 time periods (median 11.4 vs. 14.9 months), and the early mortality rate in these very elderly is high (about 30 % die within 6 months). The prognosis has particularly improved for MM patients that present with renal insufficiency. The database documents a shift in chosen therapies according to the National guidelines. Only, novel agents seem to have been less chosen for the most elderly patients.
Conclusion
Our “real life data” documents improved survival of MM patients in Denmark after 2008 and demonstrates a significant impact of National DMSG guidelines on treatment of multiple myeloma.
Session topic: E-poster
Keyword(s): Bortezomib, Multiple myeloma, Survival, Treatment
Type: Eposter Presentation
Background
Improvement of overall survival in multiple myeloma (MM) after 2000 has been reported and it has been associated with introduction of new therapeutics (Kumar, Blood 2008,111,2516-20 & Kumar, Leukemia 2014,28,1122-28). The Danish National Multiple Myeloma Registry (DMMR) was established in 2005 and has registered all patients with newly diagnosed multiple myeloma in Denmark since 1 January 2005. The Danish Myeloma Study Group (DMSG) published in 2009 the first National evidence-based guideline for treatment of MM in Denmark. The guideline recommended bortezomib based induction treatment for younger MM patients prior to HDT and for elderly patients with aggressive disease presentation and adverse cytogenetics. Moreover, lenalidomide was included in the algorithm for treatment of relapsed/progressive disease.
Aims
We aimed to analyse population-based overall survival in Danish MM patients in relation to shift in National treatment guidelines in 2009.
Methods
At 30 June 2015, the database had registered a total of 2907 patients, 991 patients <65 years and 1916 patients >65 years, with newly diagnosed treatment-demanding MM. Age-adjusted survival analyses were done per 1 September 2015.
Results
Comparing OS for patients diagnosed in the two time periods 2005-2008 and 2009-2015, we found a highly significant improved age-corrected OS in patients >65 years, increasing from median 24.7 months (2005-08) to median 32.9 months (2009-15) (p=0.003). For patients <65 years at diagnosis the overall survival also improved from median 67 months (2005-2008) to above 74 months (median OS not yet reached) (2009-2015) (p=0.02). In patients >80 years at diagnosis the survival is poor and has not improved significantly between the 2 time periods (median 11.4 vs. 14.9 months), and the early mortality rate in these very elderly is high (about 30 % die within 6 months). The prognosis has particularly improved for MM patients that present with renal insufficiency. The database documents a shift in chosen therapies according to the National guidelines. Only, novel agents seem to have been less chosen for the most elderly patients.
Conclusion
Our “real life data” documents improved survival of MM patients in Denmark after 2008 and demonstrates a significant impact of National DMSG guidelines on treatment of multiple myeloma.
Session topic: E-poster
Keyword(s): Bortezomib, Multiple myeloma, Survival, Treatment
Abstract: E1297
Type: Eposter Presentation
Background
Improvement of overall survival in multiple myeloma (MM) after 2000 has been reported and it has been associated with introduction of new therapeutics (Kumar, Blood 2008,111,2516-20 & Kumar, Leukemia 2014,28,1122-28). The Danish National Multiple Myeloma Registry (DMMR) was established in 2005 and has registered all patients with newly diagnosed multiple myeloma in Denmark since 1 January 2005. The Danish Myeloma Study Group (DMSG) published in 2009 the first National evidence-based guideline for treatment of MM in Denmark. The guideline recommended bortezomib based induction treatment for younger MM patients prior to HDT and for elderly patients with aggressive disease presentation and adverse cytogenetics. Moreover, lenalidomide was included in the algorithm for treatment of relapsed/progressive disease.
Aims
We aimed to analyse population-based overall survival in Danish MM patients in relation to shift in National treatment guidelines in 2009.
Methods
At 30 June 2015, the database had registered a total of 2907 patients, 991 patients <65 years and 1916 patients >65 years, with newly diagnosed treatment-demanding MM. Age-adjusted survival analyses were done per 1 September 2015.
Results
Comparing OS for patients diagnosed in the two time periods 2005-2008 and 2009-2015, we found a highly significant improved age-corrected OS in patients >65 years, increasing from median 24.7 months (2005-08) to median 32.9 months (2009-15) (p=0.003). For patients <65 years at diagnosis the overall survival also improved from median 67 months (2005-2008) to above 74 months (median OS not yet reached) (2009-2015) (p=0.02). In patients >80 years at diagnosis the survival is poor and has not improved significantly between the 2 time periods (median 11.4 vs. 14.9 months), and the early mortality rate in these very elderly is high (about 30 % die within 6 months). The prognosis has particularly improved for MM patients that present with renal insufficiency. The database documents a shift in chosen therapies according to the National guidelines. Only, novel agents seem to have been less chosen for the most elderly patients.
Conclusion
Our “real life data” documents improved survival of MM patients in Denmark after 2008 and demonstrates a significant impact of National DMSG guidelines on treatment of multiple myeloma.
Session topic: E-poster
Keyword(s): Bortezomib, Multiple myeloma, Survival, Treatment
Type: Eposter Presentation
Background
Improvement of overall survival in multiple myeloma (MM) after 2000 has been reported and it has been associated with introduction of new therapeutics (Kumar, Blood 2008,111,2516-20 & Kumar, Leukemia 2014,28,1122-28). The Danish National Multiple Myeloma Registry (DMMR) was established in 2005 and has registered all patients with newly diagnosed multiple myeloma in Denmark since 1 January 2005. The Danish Myeloma Study Group (DMSG) published in 2009 the first National evidence-based guideline for treatment of MM in Denmark. The guideline recommended bortezomib based induction treatment for younger MM patients prior to HDT and for elderly patients with aggressive disease presentation and adverse cytogenetics. Moreover, lenalidomide was included in the algorithm for treatment of relapsed/progressive disease.
Aims
We aimed to analyse population-based overall survival in Danish MM patients in relation to shift in National treatment guidelines in 2009.
Methods
At 30 June 2015, the database had registered a total of 2907 patients, 991 patients <65 years and 1916 patients >65 years, with newly diagnosed treatment-demanding MM. Age-adjusted survival analyses were done per 1 September 2015.
Results
Comparing OS for patients diagnosed in the two time periods 2005-2008 and 2009-2015, we found a highly significant improved age-corrected OS in patients >65 years, increasing from median 24.7 months (2005-08) to median 32.9 months (2009-15) (p=0.003). For patients <65 years at diagnosis the overall survival also improved from median 67 months (2005-2008) to above 74 months (median OS not yet reached) (2009-2015) (p=0.02). In patients >80 years at diagnosis the survival is poor and has not improved significantly between the 2 time periods (median 11.4 vs. 14.9 months), and the early mortality rate in these very elderly is high (about 30 % die within 6 months). The prognosis has particularly improved for MM patients that present with renal insufficiency. The database documents a shift in chosen therapies according to the National guidelines. Only, novel agents seem to have been less chosen for the most elderly patients.
Conclusion
Our “real life data” documents improved survival of MM patients in Denmark after 2008 and demonstrates a significant impact of National DMSG guidelines on treatment of multiple myeloma.
Session topic: E-poster
Keyword(s): Bortezomib, Multiple myeloma, Survival, Treatment
{{ help_message }}
{{filter}}